Open AccessStudy on the Therapeutic Efficacy of a Polyphitho Therapeutic Compound in Primary and Secondary Lymphedema
Author(s) -
Sandro Michelini,
Vincenzo Gasbarro,
Marcello Izzo,
Francesco Albergati
Publication year - 2021
Publication title -
lymphatic research and biology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.646
H-Index - 46
eISSN - 1557-8585
pISSN - 1539-6851
DOI - 10.1089/lrb.2019.0080
Subject(s) - medicine , lymphedema , embarrassment , physical therapy , cancer , psychology , breast cancer , social psychology
The role of the interstitial matrix in regulating exchanges and interactions at the level of the microvascular units, between the corpuscular component and the vascular and nerve structures, has long been known. Equally known are the objective and subjective clinical manifestations that these pathologies trigger in the patient, both in primary and secondary forms: embarrassment, asthenia, alterations of exteroceptive and proprioceptive sensitivity, pain, reduced capacity, and functional autonomy, affecting both the lower and the upper limbs. The authors studied 136 patients with I and II clinical stage lymphedema according to the International Society of Lymphology stadiation. Patients were treated with Lymdiaral, 20 drops three times a day for 90 consecutive days. The following parameters were examined in basal conditions and after treatment: ultrasound measurement of suprafascial thickness, short form healthy survey version 12 (SF12), body mass index, and limb circumferences in specific points of reference. The results demonstrate the effectiveness of the therapeutic principle both in the reduction of limb circumferences and in the improvement of the parameters related to the quality of life expressed by the SF12 items. There were no substantial differences in the results between primary and secondary forms.